|
1
|
Balmaña J, Díez O, Rubio LT and Cardoso F:
ESMO Guidelines Working Group: BRCA in breast cancer: ESMO clinical
practice guidelines. Ann Oncol. 22 Suppl 6:vi31–vi34. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Andrieu N, Goldgar DE, Easton DF, Rookus
M, Brohet R, Antoniou AC, Peock S, Evans G, Eccles D, Douglas F, et
al: Pregnancies, breast-feeding, and breast cancer risk in the
International BRCA1/2 Carrier Cohort Study (IBCCS). J Natl Cancer
Inst. 98:535–544. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ritte R, Tikk K, Lukanova A, Tjønneland A,
Olsen A, Overvad K, Dossus L, Fournier A, Clavel-Chapelon F, Grote
V, et al: Reproductive factors and risk of hormone receptor
positive and negative breast cancer: A cohort study. BMC Cancer.
13:5842013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee EH, Park SK, Park B, Kim SW, Lee MH,
Ahn SH, Son BH, Yoo KY and Kang D: KOHBRA Research Group; Korean
Breast Cancer Society: Effect of BRCA1/2 mutation on short-term and
long-term breast cancer survival: A systematic review and
meta-analysis. Breast Cancer Res Treat. 122:11–25. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Peshkin BN, Alabek ML and Isaacs C:
BRCA1/2 mutations and triple negative breast cancer. Breast Dis.
32:25–33. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bayraktar S, Gutierrez-Barrera AM, Liu D,
Tasbas T, Akar U, Litton JK, Lin E, Albarracin CT, Meric-Bernstam
F, Gonzalez-Angulo AM, et al: Outcome of triple-negative breast
cancer in patients with or without deleterious BRCA mutations.
Breast Cancer Res Treat. 130:145–153. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rennert G, Bisland-Naggan S,
Barnett-Griness O, Bar-Joseph N, Zhang S, Rennert HS and Narod SA:
Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2
mutations. N Engl J Med. 357:115–123. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Górski B, Byrski T, Huzarski T, Jakubowska
A, Menkiszak J, Gronwald J, Pluzańska A, Bebenek M,
Fischer-Maliszewska L, Grzybowska E, et al: Founder mutations in
the BRCA1 gene in Polish families with breast-ovarian cancer. Am J
Hum Genet. 66:1963–1968. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huzarski T, Byrski T, Gronwald J, Górski
B, Domagala P, Cybulski C, Oszurek O, Szwiec M, Gugala K, Stawicka
M, et al: Ten-year survival in patients with BRCA1-negative and
BRCA1-positive breast cancer. J Clin Oncol. 31:3191–3196. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Goodwin PJ, Phillips KA, West DW, Ennis M,
Hopper JL, John EM, O'Malley FP, Milne RL, Andrulis IL, Friedlander
ML, et al: Breast cancer prognosis in BRCA1 and BRCA2 mutation
carriers: An International Prospective Breast Cancer Family
Registry population-based cohort study. J Clin Oncol. 30:19–26.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Foulkes WD, Chappuis PO, Wong N, Brunet
JS, Vesprini D, Rozen F, Yuan ZQ, Pollak MN, Kuperstein G, Narod SA
and Bégin LR: Primary node negative breast cancer in BRCA1 mutation
carriers has a poor outcome. Ann Oncol. 11:307–313. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Stoppa-Lyonnet D, Ansquer Y, Dreyfus H,
Gautier C, Gauthier-Villars M, Bourstyn E, Clough KB, Magdelénat H,
Pouillart P, Vincent-Salomon A, et al: Familial invasive breast
cancers: Worse outcome related to BRCA1 mutations. J Clin Oncol.
18:4053–4059. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Osin P, Gusterson BA, Philp E, Waller J,
Bartek J, Peto J and Crook T: Predicted anti-oestrogen resistance
in BRCA-associated familial breast cancers. Eur J Cancer.
34:1683–1686. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Baretta Z, Mocellin S, Goldin E, Olopade
OI and Huo D: Effect of BRCA germline mutations on breast cancer
prognosis: A systematic review and meta-analysis. Medicine
(Baltimore). 95:e49752016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Van der Broek AJ, Schmidt MK, van't Veer
LJ, Tollenaar RA and van Leeuwen FE: Worse breast cancer prognosis
of BRCA1/BRCA2 mutation carriers: What's the evidence? A systematic
review with meta-analysis. PLoS One. 10:e01201892015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Robson M, Rajan P, Rosen PP, Gilewski T,
Hirschaut Y, Pressman P, Haas B, Norton L and Offit K:
BRCA-associated breast cancer: Absence of a characteristic
immunophenotype. Cancer Res. 58:1839–1842. 1998.PubMed/NCBI
|
|
17
|
Eisinger F, Stoppa-Lyonnet D, Longy M,
Kerangueven F, Noguchi T, Bailly C, Vincent-Salomon A, Jacquemier
J, Birnbaum D and Sobol H: Germ line mutation at BRCA1 affects the
histoprognostic grade in hereditary breast cancer. Cancer Res.
56:471–474. 1996.PubMed/NCBI
|
|
18
|
Osin PP and Lakhani SR: The pathology of
familial breast cancer: Immunohistochemistry and molecular
analysis. Breast Cancer Res. 1:36–40. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Armes JE, Trute L, White D, Southey MC,
Hammet F, Tesoriero A, Hutchins AM, Dite GS, McCredie MR, Giles GG,
et al: Distinct molecular pathogeneses of early-onset breast
cancers in BRCA1 and BRCA2 mutation carriers: A population-based
study. Cancer Res. 59:2011–2017. 1999.PubMed/NCBI
|
|
20
|
Crook T, Brooks LA, Crossland S, Osin P,
Barker KT, Waller J, Philp E, Smith PD, Yulug I, Peto J, et al: p53
mutation with frequent novel condons but not a mutator phenotype in
BRCA1-and BRCA2-associated breast tumors. Oncogene. 17:1681–1689.
1998. View Article : Google Scholar : PubMed/NCBI
|
